News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Naltrexone Abuse Indication Will Likely Require Monitoring and Support Services
September 20, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
EGMN -- Naltrexone is safe and effective for the treatment of opioid abuse, but the company should build on existing labeling that calls for monitoring and support as essential parts of therapy, a Food and Drug Administration advisory panel said.
Twitter
LinkedIn
Facebook
Email
Print